Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2003

View Archived Issues

Neose to develop glycoPEGylated G-CSF

Dual role of adenosine A2A receptor activation in wound healing

CytRx licenses copolymer technologies to SynthRx

Evotec and Roche enter medicinal chemistry collaboration in oncology

SBIR grant supports development of modified annexin V

A novel therapeutic role suggested for vitamin D analogues in breast cancer

PEG-sTNF-RI reported effective in improving the symptoms of rheumatoid arthritis

Good safety profile reported for i.v. LJP-1082 in antiphospholipid syndrome

Potential use of pioglitazone in the treatment of psoriatic arthritis

Beneficial effects described for OPC-28326 in Raynaud's phenomenon

Improved tear production on topical ciclosporin in Sjogren's syndrome

Antiarthritic effects of atlizumab in different patient populations

Betagenon and AstraZeneca team up to tackle type 2 diabetes

Febuxostat in the treatment of gout and hyperuricemia

New TPO receptor agonists and their use as antithrombocytopenic agents

Synthetic discorhabdin analogues and intermediates covered by Sankyo patent

Novel HDAC inhibitors isolated from a marine sponge by Yamanouchi scientists

Steryl sulfatase inhibitors identified by Kyowa Hakko researchers

Sumitomo reports the discovery and testing of naturally produced neuroprotectants

Novel gluconeogenesis inhibitors under study at Sumitomo

Yamanouchi describes new antitumor agents from Pseudomonas species

Bay-43-9006 enters pivotal phase III trial in kidney cancer

Cyberonics submits PMA-S for VNS Therapy

EN-3247 fails to prevent oral mucositis in pivotal trial

Remicade reduces signs and symptoms of anklyosing spondylitis in ASSERT trial

Phase I IND cleared for T-62

Daivobet effective in severe psoriasis

Extended phase II data show RA patients benefit from MabThera for up to 48 weeks

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...